Gerd supports Apollo and its portfolio as an Executive Vice President R&D
He has more than 20 years of experience in the pharma and biotech industry R&D and previously led R&D at Jerini AG and OryzonGenomics. Oryzon develops novel therapeutics based on epigenetics
Gerd has a broad experience in the development of small molecules, peptides and peptidomimetics covering a wide range of therapeutic areas and therefore can provide highly valuable guidance in shaping R&D
Before consulting international biotech companies, he received his PhD in organic chemistry from University of Konstanz
Gerd supports Apollo and its portfolio as an Executive Vice President R&D
He has more than 20 years of experience in the pharma and biotech industry R&D and previously led R&D at Jerini AG and OryzonGenomics. Oryzon develops novel therapeutics based on epigenetics
Gerd has a broad experience in the development of small molecules, peptides and peptidomimetics covering a wide range of therapeutic areas and therefore can provide highly valuable guidance in shaping R&D
Before consulting international biotech companies, he received his PhD in organic chemistry from University of Konstanz
